ArticlePLoS neglected tropical diseases2019
Utility of rabies neutralizing antibody detection in cerebrospinal fluid and serum for ante-mortem diagnosis of human rabies.
Article in PLoS neglected tropical diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Survival Following Paralytic Rabies Encephalomyelitis in a Toddler: Challenges in Confirmation of Diagnosis.Indian journal of pediatrics · 2026Article
- Detectability of Pathogenic RNA Virus Families in Different Body Sites: A Scoping Review.Viruses · 2026Article
- High sensitivity of the Bionote Anigen Rapid Rabies Antigen Test in detection of diverse rabies virus variants suggests utility for global rabies control.Journal of clinical microbiology · 2026Article
- A Case Report of Rabies in an HIV Patient: Diagnostic Challenges and Near-Miss Recognition.Infection and drug resistance · 2026Article
- The Diagnosis of Human Neurological Infection Caused by Rabies Virus Using Metagenomic Next-Generation Sequencing: Two Case Reports.Case reports in infectious diseases · 2026Article
- Metagenomic Next-Generation Sequencing Unmasks Atypical Rabies - Guangxi Zhuang Autonomous Region, China, 2024.China CDC weekly · 2025Article
- A QS21+ CpG-Adjuvanted Rabies Virus G Subunit Vaccine Elicits Superior Humoral and Moderate Cellular Immunity.Vaccines · 2025Article
- Recent updates on laboratory diagnosis of rabies.The Indian journal of medical research · 2024Review
- Case Report: Survival from Clinical Rabies in a Young Child from Maharashtra, India, 2022.The American journal of tropical medicine and hygiene · 2023Article
- Characterisation of a Live-Attenuated Rabies Virus Expressing a Secreted scFv for the Treatment of Rabies.Viruses · 2023Article
- Metagenomic next-generation sequencing for the etiological diagnosis of rabies virus in cerebrospinal fluid.Frontiers in medicine · 2023Article
- Intravitam Diagnosis of Rabies in Patients with Acute Encephalitis: A Study of Two Cases.Infectious disease reports · 2022Article
- Early diagnosis of rabies virus infection by RPA-CRISPR techniques in a rat model.Archives of virology · 2021Article
- Antemortem diagnosis of human rabies: A case report.Clinical case reports · 2021Article
- Prevalence and Epitope Recognition of Anti-Pathogens (Basel, Switzerland) · 2020Article
- Human rabies in China: evidence-based suggestions for improved case detection and data gathering.Infectious diseases of poverty · 2020Article
- Survival in human rabies but left against medical advice and death followed - Community education is the need of the hour.Journal of family medicine and primary care · 2020Article
- Selection and preliminary application of a single stranded DNA aptamer targeting colorectal cancer serum.RSC advances · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly ante-mortem laboratory confirmation of human rabies is essential to aid patient management and institute public health measures. Few studies have highlighted the diagnostic value of antibody detection in CSF/serum in rabies, and its utility is usually undermined owing to the late seroconversion and short survival in infected patients. This study was undertaken to examine the ante-mortem diagnostic utility and prognostic value of antibody detection by rapid fluorescent focus inhibition test (RFFIT) in cerebrospinal fluid (CSF)/serum samples received from clinically suspected human rabies cases from January 2015 to December 2017. METHODOLOGY/PRINCIPAL
findingsSamples collected ante-mortem and post-mortem from 130 and 6 patients with clinically suspected rabies respectively, were received in the laboratory during the study period. Ante-mortem laboratory confirmation was achieved in 55/130 (42.3%) cases. Real time PCR for detection of viral nucleic acid performed on saliva, nuchal skin, brain tissue and CSF samples could confirm the diagnosis in 15 (27.2%) of the 55 laboratory confirmed cases. Ante-mortem diagnosis could be achieved by RFFIT (in CSF and/or serum) in 45 (34.6%) of the 130 clinically suspected cases, accounting for 81.8% of the total 55 laboratory confirmed cases. The sensitivity of CSF RFFIT increased with the day of sample collection (post-onset of symptoms) and was found to be 100% after 12 days of illness. Patients who had received prior vaccination had an increased probability of a positive RFFIT and negative PCR result. Patients who were positive by RFFIT alone at initial diagnosis had longer survival (albeit with neurological sequelae) than patients who were positive by PCR alone or both RFFIT and PCR. CONCLUSIONS/SIGNIFICANCE: Detection of antibodies in the CSF/serum is a valuable ante-mortem diagnostic tool in human rabies, especially in patients who survive beyond a week. It was also found to have a limited role as a prognostic marker to predict outcomes in patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.